INBRAIN Neuroelectronics' Groundbreaking Funding
INBRAIN Neuroelectronics, a pioneering company in brain-computer interface therapeutics (BCI-Tx), has successfully closed a $50 million Series B financing round. This funding aims to propel the advancement of their cutting-edge graphene-based neural technologies. The financing was led by imec.xpand alongside a group of new investors including EIC Fund, Fond ICO Next Tech, CDTI-Innvierte, and Avançsa. Existing investors such as Asabys Partners, Aliath Bioventures, and Vsquared also contributed, bringing total investment since inception to $68 million.
Strengthening Partnerships and Advancements in Technology
Beyond the financial contributions from the Series B round, INBRAIN has also received additional backing from Merck KGaA. This partnership promises to further advance the clinical development of INBRAIN’s innovative technology, specifically targeting areas where Merck has a vested interest. This collaboration will greatly enhance the integration of INBRAIN’s platform for broader applications across both the central and peripheral nervous systems.
Revolutionary Graphene Technology
At the core of INBRAIN’s technology is graphene, a celebrated material renowned for its strength, flexibility, and remarkable conductivity. INBRAIN’s neural implant measures just 10 micrometers in thickness—making it thinner than a human hair. This design allows for highly accurate decoding and modulation of neural signals, facilitating an enhanced performance in the dynamic field of precision neurology. The funding will significantly expedite the advancement of INBRAIN’s graphene-based BCI-Tx platform, which enables a bidirectional decoding and modulation of neural activity with unprecedented clarity.
Driving Innovation in Patient-Centric Treatments
In a statement about the funding, Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics, expressed enthusiasm, stating, “We’re shaping the future of brain-computer interface therapeutics. This funding empowers us to advance our AI-driven graphene neurotechnology, which has demonstrated promising results compared to existing commercial neuromodulation technology. We are thrilled to have the support of a top-tier syndicate as we strive to deliver this technology to patients who truly need precise and personalized treatments.”
Collaboration with Leading Nanoelectronics Hub
A significant component of the funding initiative includes a collaboration with imec, recognized as the world’s leading independent hub for nanoelectronics. This partnership aims to help INBRAIN prepare for the commercial-scale production of graphene interfaces, positioning them at the forefront of neurological technology development.
Groundbreaking Clinical Trials
Recently, INBRAIN achieved a notable milestone: the successful implementation of the world’s first human application of its graphene-based BCI in a clinical trial at a prominent health facility. This trial aims to evaluate the safety and efficacy of INBRAIN’s device in patients diagnosed with brain cancer, with plans to enroll up to ten participants. The objectives focus on assessing the advantages of graphene compared to traditional materials used in neural applications.
Shaping the Future of Neurotechnology
Marcin Nowak, Investment Director at the European Investment Bank, shared insights on INBRAIN’s recent funding as well, stating, “The success of INBRAIN’s first patient procedure and funding reflects the innovative vision that initiated the Graphene Flagship project. By leveraging graphene’s remarkable abilities, INBRAIN is well-positioned to advance pioneering neurotechnology applications, potentially revolutionizing treatment outcomes for patients and affirming Europe’s role in the global BCI industry.”
About INBRAIN Neuroelectronics
INBRAIN Neuroelectronics is revolutionizing the field of real-time precision neurology with the development of the world’s first graphene-based brain-computer interface therapeutics (BCI-Tx) platform. The technology employs advanced methods for neural decoding and micrometric modulation, enabling personalized and adaptive therapies for various neurological conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. Their innovative approach continuously monitors and adjusts treatment in real-time, significantly improving outcomes while minimizing side effects. This groundbreaking development has already earned INBRAIN the FDA Breakthrough Device Designation for its BCI-Tx aimed at treating Parkinson’s Disease. Through collaborations with partners such as Merck KGaA and its subsidiary INNERVIA Bioelectronics, INBRAIN is committed to extending these innovations into the treatment of peripheral nerve and systemic diseases, thus paving the way for a new era in neurotechnology and bioelectronics.
Frequently Asked Questions
What is INBRAIN Neuroelectronics focusing on with their technology?
INBRAIN aims to develop advanced brain-computer interface therapeutics using graphene technology for more precise and personalized treatment of neurological conditions.
How much funding did INBRAIN raise in their Series B round?
INBRAIN raised $50 million in their Series B financing round, enhancing their ability to advance their innovative technology.
What role does Merck KGaA play in INBRAIN's development?
Merck KGaA is providing additional funding and support, helping to propel the clinical development of INBRAIN’s technology in therapeutic areas of their interest.
What milestone has INBRAIN recently achieved?
INBRAIN successfully implemented the world’s first human application of their graphene-based BCI during a clinical trial aimed at assessing its safety in patients with brain cancer.
How does INBRAIN’s device compare to traditional neural applications?
INBRAIN’s graphene-based device is designed to offer improved accuracy and effectiveness when decoding and modulating neural signals, providing significant advantages over traditional devices.
